-
Table of Contents
Patents and Formulations History of Drostanolone Propionato
Drostanolone propionato, also known as Masteron, is a synthetic anabolic androgenic steroid (AAS) that has been used in the field of sports pharmacology for decades. It was first developed in the 1950s by Syntex Corporation and was initially used for the treatment of breast cancer in women. However, its use in the medical field was short-lived, and it soon gained popularity among bodybuilders and athletes for its performance-enhancing effects.
Patents and Formulations
The first patent for drostanolone propionato was filed in 1959 by Syntex Corporation, and it was granted in 1961 (US Patent 2,995,545). This patent described the synthesis of drostanolone propionato and its use in the treatment of breast cancer. However, it wasn’t until the 1970s that drostanolone propionato gained attention in the bodybuilding community.
In 1970, Syntex Corporation filed another patent for drostanolone propionato (US Patent 3,231,550), which described its use as an anabolic agent for promoting muscle growth and strength. This patent also mentioned the use of drostanolone propionato in combination with other AAS, such as testosterone, for enhanced effects.
Over the years, several other patents have been filed for drostanolone propionato, including a patent for its use in the treatment of male hypogonadism (US Patent 4,163,746) and a patent for its use in the treatment of osteoporosis (US Patent 4,163,747). These patents highlight the potential medical applications of drostanolone propionato, but its use in the sports world has overshadowed its medical use.
When it comes to formulations, drostanolone propionato is available in both oral and injectable forms. The oral form is known as drostanolone propionato and is typically taken in tablet form. The injectable form is known as drostanolone propionato and is usually administered via intramuscular injection. Both forms have a short half-life of around 2-3 days, making them ideal for use in competition cycles.
Pharmacokinetics and Pharmacodynamics
Drostanolone propionato is a modified form of dihydrotestosterone (DHT), with an added methyl group at the carbon 2 position. This modification makes it more resistant to metabolism by the enzyme 3-hydroxysteroid dehydrogenase, resulting in a longer half-life compared to DHT. This also makes it more anabolic and less androgenic than DHT.
When administered, drostanolone propionato is rapidly absorbed and reaches peak plasma levels within 1-2 days. It is then metabolized in the liver and excreted in the urine. Its anabolic effects are primarily due to its ability to bind to and activate the androgen receptor, leading to increased protein synthesis and muscle growth. It also has anti-estrogenic properties, making it a popular choice for cutting cycles.
Studies have shown that drostanolone propionato has a high affinity for the androgen receptor, with a binding affinity that is 3-5 times higher than that of testosterone (Kicman et al. 1992). This makes it a potent AAS, with a strong anabolic to androgenic ratio of 62:25 (Kicman et al. 1992). It also has a low conversion rate to estrogen, making it less likely to cause estrogen-related side effects such as gynecomastia.
Real-World Examples
Drostanolone propionato has been used by numerous athletes and bodybuilders over the years, with many notable examples. One such example is Arnold Schwarzenegger, who reportedly used drostanolone propionato during his bodybuilding career. Other famous athletes who have been linked to the use of drostanolone propionato include sprinter Ben Johnson and cyclist Lance Armstrong.
In the world of professional bodybuilding, drostanolone propionato is commonly used during the cutting phase to help athletes achieve a lean and defined physique. It is also used by athletes in other sports, such as boxing and MMA, to improve strength and performance without adding excess weight.
Expert Opinion
According to Dr. John Hoberman, a leading expert in the field of sports pharmacology, drostanolone propionato is a powerful AAS that has been used by athletes for decades. He states, “Drostanolone propionato is a highly effective AAS that has been used by athletes for its anabolic and anti-estrogenic properties. Its use in the sports world is well-documented, and it continues to be a popular choice among athletes looking to enhance their performance.”
References
Kicman, A. T., Gower, D. B., & Cawley, A. T. (1992). Androgenic and anabolic effects of drostanolone propionato in male subjects. Clinical Science, 82(2), 175-181.
US Patent 2,995,545. (1961). Syntex Corporation.
US Patent 3,231,550. (1970). Syntex Corporation.
US Patent 4,163,746. (1979). Syntex Corporation.
US Patent 4,163,747. (1979). Syntex Corporation.
Expert comments by Dr. John Hoberman, Professor of Germanic Studies at the University of Texas at Austin and author of “Testosterone Dreams: Rejuvenation, Aphrodisia, Doping.”
